908 DEVICES INC. Research and Development Expense
908 DEVICES INC. (MASS) reported Research and Development Expense of $3.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- 908 DEVICES INC. research and development expense for the quarter ending 2026-06-30 was $3.60M, a 18.32% decline year-over-year.
- 908 DEVICES INC. research and development expense for the quarter ending 2026-03-31 was $3.47M, a 9.35% decline year-over-year.
- 908 DEVICES INC. research and development expense for the quarter ending 2025-12-31 was $3.50M, a 10.15% decline year-over-year.
- 908 DEVICES INC. research and development expense for the quarter ending 2025-09-30 was $3.84M, a 8.75% decline year-over-year.
- 908 DEVICES INC. research and development expense for fiscal 2025 was $15.57M, a 3.92% increase from fiscal 2024.
- 908 DEVICES INC. research and development expense for fiscal 2024 was $14.99M, a 31.57% decline from fiscal 2023.
- 908 DEVICES INC. research and development expense for fiscal 2023 was $21.90M, a 24.98% increase from fiscal 2022.
- 908 DEVICES INC. research and development expense for fiscal 2022 was $17.53M, a 34.12% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.60M 10-Q · filed 2026-08-11 | $7.07M 10-Q · filed 2026-08-11 | $10.57M derived: sum of 3 quarters · filed 2026-08-11 | $14.41M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $3.47M 10-Q · filed 2026-05-06 | $6.97M derived: sum of 2 quarters · filed 2026-05-06 | $10.81M derived: sum of 3 quarters · filed 2026-05-06 | $15.22M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $7.34M derived: sum of 2 quarters · filed 2026-03-09 | $11.75M derived: sum of 3 quarters · filed 2026-08-11 | $15.57M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $3.84M 10-Q · filed 2025-11-10 | $8.24M derived: sum of 2 quarters · filed 2026-08-11 | $12.07M 10-Q · filed 2025-11-10 | $15.97M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $4.41M 10-Q · filed 2026-08-11 | $8.23M 10-Q · filed 2026-08-11 | $12.13M derived: sum of 3 quarters · filed 2026-08-11 | $16.34M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $3.83M 10-Q · filed 2026-05-06 | $7.73M derived: sum of 2 quarters · filed 2026-05-06 | $11.93M derived: sum of 3 quarters · filed 2026-05-06 | $15.53M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $8.11M derived: sum of 2 quarters · filed 2026-03-09 | $11.70M derived: sum of 3 quarters · filed 2026-03-09 | $14.99M 10-K · filed 2026-03-09 | $25.50M 10-K · filed 2025-03-07 | |||
| 2024-09-30 | $4.21M 10-Q · filed 2025-11-10 | $6.79M 10-Q · filed 2024-11-12 | $7.80M derived: sum of 2 quarters · filed 2025-11-10 | $11.09M 10-Q · filed 2025-11-10 | $18.96M 10-Q · filed 2024-11-12 | $16.53M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $3.59M 10-Q · filed 2025-08-05 | $6.38M 10-Q · filed 2024-08-06 | $6.88M 10-Q · filed 2025-08-05 | $12.17M 10-Q · filed 2024-08-06 | $12.33M derived: sum of 3 quarters · filed 2025-08-05 | $17.86M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $3.29M 10-Q · filed 2025-05-13 | $5.79M 10-Q · filed 2024-05-03 | $8.74M derived: sum of 2 quarters · filed 2025-05-13 | $14.27M derived: sum of 3 quarters · filed 2025-05-13 | $19.80M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $5.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $10.98M derived: sum of 2 quarters · filed 2025-03-07 | $16.51M derived: sum of 3 quarters · filed 2025-03-07 | $21.90M 10-K · filed 2025-03-07 | ||||
| 2023-09-30 | $5.54M 10-Q · filed 2024-11-12 | $11.06M derived: sum of 2 quarters · filed 2024-11-12 | $16.46M 10-Q · filed 2024-11-12 | $21.12M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $5.53M 10-Q · filed 2024-08-06 | $10.92M 10-Q · filed 2024-08-06 | $15.59M derived: sum of 3 quarters · filed 2024-08-06 | $20.25M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $5.40M 10-Q · filed 2024-05-03 | $10.06M derived: sum of 2 quarters · filed 2024-05-03 | $14.73M derived: sum of 3 quarters · filed 2024-05-03 | $19.02M derived: sum of 4 quarters · filed 2024-05-03 | ||||
| 2022-12-31 | $4.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $9.33M derived: sum of 2 quarters · filed 2024-03-08 | $13.62M derived: sum of 3 quarters · filed 2024-03-08 | $17.53M 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | $4.67M 10-Q · filed 2023-11-07 | $8.96M derived: sum of 2 quarters · filed 2023-11-07 | $12.86M 10-Q · filed 2023-11-07 | $16.61M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $4.29M 10-Q · filed 2023-08-08 | $8.20M 10-Q · filed 2023-08-08 | $11.94M derived: sum of 3 quarters · filed 2023-08-08 | $15.24M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $3.90M 10-Q · filed 2023-05-09 | $7.65M derived: sum of 2 quarters · filed 2023-05-09 | $10.95M derived: sum of 3 quarters · filed 2023-05-09 | $14.01M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $7.05M derived: sum of 2 quarters · filed 2023-03-15 | $10.10M derived: sum of 3 quarters · filed 2023-03-15 | $13.07M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $3.30M 10-Q · filed 2022-11-14 | $6.36M derived: sum of 2 quarters · filed 2022-11-14 | $9.32M 10-Q · filed 2022-11-14 | $11.60M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $3.06M 10-Q · filed 2022-08-09 | $6.02M 10-Q · filed 2022-08-09 | $8.30M derived: sum of 3 quarters · filed 2022-08-09 | $10.25M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $2.96M 10-Q · filed 2022-05-10 | $5.25M derived: sum of 2 quarters · filed 2022-05-10 | $7.20M derived: sum of 3 quarters · filed 2022-05-10 | $9.04M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $4.23M derived: sum of 2 quarters · filed 2022-03-11 | $6.08M derived: sum of 3 quarters · filed 2022-03-11 | $8.23M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $1.95M 10-Q · filed 2021-11-04 | $3.80M derived: sum of 2 quarters · filed 2021-11-04 | $5.95M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $1.85M 10-Q · filed 2021-08-04 | $4.00M 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | $2.16M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |